



# Annual Report

## 2024

The central resource for  
the Swiss biotech industry



## Impressum

Publisher: Swiss Biotech Association  
Concept and text: Sabine Barnert, Michael Altorfer, Swiss Biotech Association  
Layout: Thomas Schicker Konzeption und Gestaltung, Zürich  
Pictures: Swiss Biotech Association  
Print: Schmid-Fehr AG  
Climate-neutral print on wood-free, matt coated paper



# Contents

Swiss biotech industry – A trusted partner in times of global instability	4
The Swiss biotech community is expanding its impact	5
Highlights of the Swiss Biotech Association in 2024	6
Swiss Biotech Ventures: Financing and partnering	8
Swiss Biotech Orbit: Matching talent and opportunities	9
Development in numbers	10
The Swiss Biotech Association	
Our stakeholders: Who we support and represent	11
Our mission: Representing the interests of the industry	12
Empowering biotechs: Support across essential areas	13
Our powerful platforms: How we bring our mission to life	14
Promoting accomplishments of the industry	16
Swiss Biotech Success Stories	18
In the media	24
Partner network	26
Financial statements 2024	28
Focus on what really matters	31
Preferential business solutions for our members	34
Swiss Biotech Association board and management	36
Supporting the Swiss biotech hub: Objectives 2025	38
Our members	40

## A trusted partner in times of global instability



**In a world marked by global instability – wars, political shifts, and a trend back towards local, territorial protectionism – the need to uphold scientific integrity, a strong life science voice and trusted international collaborations has never been greater. This moment presents a unique opportunity for Switzerland to solidify our role as a trusted and stable partner, fostering enduring collaborations.**

Despite fewer investments and a higher bar for funding, investment and dealmaking within the biotech sector in Switzerland has remained stable.

We witnessed several encouraging and impressive financing rounds, including companies such as Alentis, Asceneuron Bright Peaks, Cradle, iOnctura, Neurosterix, Numab, Windward Bio, and others. Notable partnering deals include those of AC Immune/Takeda, Araris/Chugai, Haya/Lilly, Numab/JnJ, Vir/Sanofi and Molecular Partners/Oranomed.

The investments and deal flow are largely in line with the global focus of biotech VCs and pharma, including AI-driven protein engineering, obesity treatments, radio-pharmaceuticals, antibody-drug conjugates (ADCs), and a somewhat renewed interest in immuno-oncology (including PDL-1/VEGF and T-cell engagers).

Additionally, there is a trend of increased deal activity with Chinese companies that deserves our attention. For every drug, mostly antibodies, there is a me-too or me-better in a Chinese pipeline. This has become a strategic hunting ground for in-licensing and/or acquisition for VCs, biotech, or pharma. Swiss biotech companies and VCs are capitalizing on this, and at the same time, it is both an opportunity and a necessity to differentiate our “Swiss-originated” pipeline as being a step ahead of this competition.

At the Swiss Biotech Association, we continue to support our members through various initiatives, tailoring our efforts

to their key needs. This includes the Swiss Biotech Day, and meetings for biotech CEOs, CFOs, and HR leaders. We have also continued our collaboration with Swissmedic to support the evolution of the local trial landscape. At the association’s level, we are pleased to welcome Igor Fisch as a new member of our board of directors, bringing his entrepreneurial expertise and passion for mentoring the next generation.

Given the unstable global situation, social impact remains an important pillar at our association. In 2024, we founded Life Science Cares (LSC), bridging the needs of our less privileged citizens with support and opportunities in the life science community. This initiative aims to break the cycle of poverty and demonstrates our commitment to making a positive impact beyond the biotech industry. We extend our gratitude to our LSC founding partners for their support: HBM, Numab, OM Pharma, CDR Life, Molecular Partners, and Wyss Zurich.

We look forward to a successful year ahead and to welcoming you at the Swiss Biotech Day on May 5 and 6, where we will share valuable insights and updates on our efforts to drive the success of the Swiss biotech industry.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'P. Amstutz', written in a cursive, flowing style.

Patrick Amstutz  
President Swiss Biotech Association



# The Swiss biotech community is expanding its impact



**The Swiss biotech community is making a growing impact – and this is being noticed internationally. For the second year in a row, more than 100 new members have joined the Swiss Biotech Association, expanding its member base to 593 members. The Swiss Biotech Report 2024 revealed that Swiss biotech companies attracted more than 2 billion CHF in new funds and invested approximately 2.5 billion CHF in their R&D projects.**

International business partners are noticing this strong development, and the Swiss Biotech Day expanded by another 40%, attracting around 2,500 attendees, with more than 40% joining from abroad.

A key driver is the Global Village platform. Embedded in the Swiss Biotech Day, it supports international delegations in strengthening their ties with Swiss biotech leaders. From 10 delegations in 2023, the number rose to 17 in 2024, with over 20 expected this year.

To build on this success, a biotech investor pre-event is planned, alongside other innovations like mentoring booths, Swiss cluster booths, and moderated networking sessions to foster collaboration and generate qualitative growth.

In 2024 alone, the Swiss Biotech Association welcomed 112 new members. We greatly appreciate this positive feedback and sign of trust, as it provides us with greater financial flexibility and strengthens our credibility with policymakers and international partners.

In 2024, we used this support to:

- ✓ Expand the peer-to-peer meetings to connect CEOs, CFOs, and Swiss biotech HR leaders
- ✓ Further accelerate the onboarding to the Swiss Biotech Ventures (financing & partnering) and Swiss Biotech Orbit (talent matching) platforms
- ✓ Build up the association chapters for diagnostics, healthtech, and industrial biotech companies, as well as the expert chapter for tax, legal, and accounting

- ✓ Provide strong advocacy through our collaborations with Interpharma, scienceindustries, economiesuisse, and the International Council of Biotech Associations.
- ✓ Promote the Swiss biotech hub as a valuable partner in international collaborations and alliances, showcasing, e.g., the Access Consortium of Swissmedic (joint approval with Australia, Canada, the UK, and Singapore) or new partners for healthcare innovation, such as the Botnar Institute of Immune Engineering, which was founded in Basel last year.
- ✓ Promote the value and contribution of the Swiss biotech industry: Dr. Hans-Peter Strebel and the Swiss Foundation for Research on Muscle Diseases were honored with the Swiss Biotech Success Stories Award.

Our objectives for 2025 are outlined on pages 38-39. Please reach out to our board members and the management team (see page 36) with your feedback and support us in providing a strong voice for the Swiss biotech ecosystem.

Yours faithfully,

Michael Altörfer  
CEO

## Highlights of the Swiss Biotech Association in 2024



Our flagship event, the **Swiss Biotech Day**, once again fostered collaboration and impactful partnerships. In 2024, 2,500 participants from 40+ countries, including 17 international delegations, joined this premier global biotech conference. Since 2021, attendance has grown by 40% annually, underscoring its rising influence in life sciences. At the Swiss Biotech Day we also supported the **Swiss launch of the first international chapter of Life Science Cares**, building bridges for people with limited opportunities and connecting the life science community with local non-profit organizations.

Our **Swiss Biotech Report 2024**, outlined capital investments in Swiss biotech of CHF 2 billion and R&D investments aggregating to CHF 2.5 billion.

Switzerland's most comprehensive **Swiss Biotech Directory** with over 1,500 company entries was printed and distributed to stakeholders in Switzerland and at leading international biotech conferences.

Our **platforms supporting all Swiss biotech companies** continue to grow: Swiss Biotech Ventures for funding, Global Village for international collaboration, and Swiss Biotech Orbit for talent acquisition.

We represented the Swiss biotech industry in the International Council of Biotechnology Associations' (ICBA).

We support the ICBA in talks with the **WHO, WTO, and WIPO**, by emphasizing the needs of innovative biotech startups and SMEs.

Swiss biotech and the association were presented in the **Swiss pavilions at BIO International and the BIO Europe** conventions, at the Sachs Associates' investor conferences, Illmac, and many more.

At our general assembly, Igor Fisch was elected as a new **board member**, while departing members Luca Bolliger and Ulf Grawunder were awarded honorary membership in appreciation of their many years of dedicated support and representation of the association.



Interest in **targeted peer-to-peer meetings for biotech executives** is growing among our members as a valuable forum for informal exchange of best practices. Building on the success of the Swiss biotech CEO meeting, the CFO and HR leaders meetings have drawn executives to discuss their unique challenges in the biotech industry in a relaxed, interactive setting. These gatherings will continue to foster collaboration, enabling to shape optimal frameworks for peer exchange, set priorities, and address strategic issues.



## Swiss Biotech Ventures platform

**Swiss biotech companies, global biotech investors and industry partners equally benefit from the Swiss Biotech Ventures platform. It is free of charge and matches Swiss biotech companies, global biotech investors, and industry partners to facilitate financing, licensing and research collaborations.**

With the Swiss Biotech Ventures platform, the Swiss Biotech Association enables Swiss biotech companies to present their investment and partnership opportunities to global biotech investors and multinational pharma and industry partners. Investors, family offices, foundations and pharmaceutical companies gain insight into the pipeline of the Swiss biotech hub, and easily discover and contact companies matching their strategic focus based on modalities, indications, and development stage.

Swiss Biotech Ventures is a comprehensive database that creates transparency between stakeholders. On the “sell side”, Swiss biotech companies describe their value proposition. On the “buy side”, global biotech investors and pharmaceutical representatives identify investment and partnership opportunities matching with their selection criteria. Both sides present their focus and goals, rendering matchmaking between these players efficient and transparent.

Swiss Biotech Ventures is steadily growing. At the beginning of 2025, more than 1,000 investors and pharmaceutical companies were listed, and about 240 innovative venture projects from Swiss biotech companies were presented. Every time a venture matching the selection criteria of an investor is added, or its status changes (e.g. from preclinical to clinical phase I), interested parties receive an email notification and can find out more on the platform.

Both sides gain valuable time as individual communication on the project development is replaced by timely, transparent and consistent information. In the Swiss tradition, the Swiss Biotech Association takes a neutral stance. No company is promoted,

no privileged information is shared with any of the parties, nor does the Swiss Biotech Association receive any success fee. Anyone on the platform has free access to identical information, simultaneously, transparently and to the benefit of all parties.

In conjunction with the Swiss Biotech Ventures platform, the Swiss Biotech Association also helps companies to present and partner at the Swiss Biotech Day and at national and international events. Quarterly highlight reports from the Swiss biotech industry with background information complete the offering.

**SWISS+**  
**BIOTECH™**  
Ventures

### Join Swiss Biotech Ventures and gain access to:

- ▶ free of charge platform, by invitation only
- ▶ matching Swiss biotech companies with global biotech investors and industry partners to facilitate financing, licensing and research collaboration
- ▶ timely, transparent, simultaneous, and consistent information
- ▶ a steadily growing database of thriving biotech ventures
- ▶ free newsletters on Swiss biotech venture highlights and background information



Use this QR code to register on Swiss Biotech Ventures and promote the platform amongst your peers around the globe



# Swiss Biotech Orbit: Matching talent and opportunities



## Bridging talents to biotech brilliance

The Orbit platform is available to biotech talent in Switzerland and abroad. Biotech companies in Switzerland can use the platform to search this talent pool without the need to publicly publish open positions.

Swiss Biotech Orbit helps to match job opportunities and talents, and supports all Swiss biotech companies that can offer job opportunities.



**The Orbit platform features a wide range of local talent, with searching and filtering tools to help you find the right person for the job.**

David Pejowski, Co-founder and Co-CEO,  
Adoram Therapeutics

## Rapidly expanding

The non-public Swiss Biotech Orbit talent platform matches the skills of talents with the criteria of job offers. Since its launch, numerous life science companies and talents have joined, and more are joining every day, contributing to the rapid expansion of the platform.

Swiss Biotech Orbit opens doors to exciting opportunities for professionals, and future talents in life sciences R&D, and supports Swiss biotech companies in identifying the right talent in the industry.

**SWISS+  
BIOTECH™**  
Orbit

## How to get involved

Swiss Biotech Orbit can only be successful with the support of our members and other stakeholders in the industry. We encourage you to join Swiss Biotech Orbit and contribute to the growth of the life science industry in Switzerland.



Use this QR code to match talents and opportunities

## Development in numbers

At the end of 2024, the Swiss Biotech Association counted 593 members. Our website, newsletters, social media activities, and mailings provide an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry. The number of members, subscribers and website visitors is steadily increasing.



# The Swiss Biotech Association


Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access

to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.



## Our stakeholders: Who we support and represent

**The Swiss Biotech Directory lists more than 1,500 companies, reflecting both the rapid growth, as well as the diversity of this vibrant economic sector. The Swiss biotech industry has built one of the most densely populated and comprehensive biotech ecosystems worldwide.**



Highly specialized clinical research organizations, manufacturers, suppliers and technical consultants complement, support, and advise biotech companies which focus on the development of their proprietary product pipelines.

Many of the globally leading CROs and suppliers have selected Switzerland as their international headquarter, and Swiss biotech

companies benefit from the proximity of Roche and Novartis and numerous international pharma companies. Increasingly, international companies select Switzerland as their hub for the production of highly complex biologics, peptides and cell products. International investors and industry specialists alike, value the numerous advantages Switzerland offers.

# Our mission: Representing the interests of the industry

**The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.**



Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation. To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

## **Developing favorable and competitive framework conditions**

- ▶ Creating awareness of the biotech industry's needs and interests with policy makers
- ▶ Advocating a competitive tax system alongside lean and pragmatic regulations
- ▶ Fostering life science education, technology transfer and intellectual property

## **Attracting talent, know-how and financial resources to drive innovation and growth**

- ▶ Promoting and facilitating access to funding opportunities
- ▶ Connecting investors and attractive biotech investment opportunities
- ▶ Facilitating access to national and international talent

## **Fostering networking through strategic, national and international partnerships**


- ▶ Connecting industry stakeholders and life science clusters
- ▶ Organizing and co-promoting national and international life science events
- ▶ Providing access to privileged information through industry platforms and working groups

## **Promoting the accomplishments of the Swiss biotech industry**

- ▶ Disseminating the value-creation of Swiss biotech companies
- ▶ Visualizing the diversity and competitiveness of Swiss biotech companies
- ▶ Presenting innovative products and technologies and their contribution to quality of life



Empowering biotechs: Support across essential areas



# Our powerful platforms: How we bring our mission to life

The Swiss Biotech Association is committed to creating and maintaining platforms that benefit all Swiss biotech companies – not only its members – in financing and partnering, search for talent and in education, branding, and networking: We unite people to collaboratively shape the ideal framework conditions for a vibrant Swiss biotech community and beyond.



## Boosting global visibility

By promoting biotech companies in the Swiss Biotech Directory, by disseminating their news, and with success stories



## Financing and partnering

By connecting Swiss R&D biotech companies with global investors and industry partners on Swiss Biotech Ventures



## Finding talent internationally


By matching Swiss job opportunities and talents on Swiss Biotech Orbit



## Foster International collaboration

By uniting foreign biotech clusters with the Swiss biotech ecosystem through our Global Village





Our event platforms offer real networking to let executives and professionals discuss their unique needs in a relaxed, peer-to-peer setting. Crucial in a fast-evolving industry, face-to-face interactions accelerate innovation, strengthen partnerships, and help shape the future of a thriving Swiss biotech community.



## The Swiss Biotech Day

For international networking at one of the leading global biotech conferences, with thousands of guests



## Professional development and education

Offered at the Swiss Biotech Association Academy by academic institutions & regular Swiss Biotech Insight meetings

## Swiss biotech CEO meetings

The exclusive and informal annual networking event for Swiss R&D biotech CEOs

## Swiss biotech CFO meetings

To openly share and discuss unique requirements as a CFO in the biotech sector


## Swiss biotech HR leaders meetings

A day to shape business culture, leadership, and talent management in the biotech industry




swissbiotech.org is a valuable information source for the industry, offering an up-to-date and comprehensive view of the Swiss biotech sector. This is reflected in a steadily growing number of website visitors.





### The newsletter from the central resource for the Swiss biotech industry

November 2024




#### November 21: Informal exchange in Basel Social partnerships for life science companies

Life Science Cares Switzerland is a newly founded organization with the aim of linking the life science community with local charitable organizations to facilitate access to education for socially disadvantaged people in Switzerland and thereby strengthen the life science industry. [Join the apéro and register now.](#)

#### New database

##### Locate regulatory and ethical information for clinical research

The European Clinical Research Infrastructure Network, ECRIN, has launched its [regulatory and ethical database - RED](#). This tool is designed to support the European clinical research community with essential resources and guidance. Whether you are planning a multi-country study or expanding an existing project across borders, RED offers precise, up-to-date information to navigate the complexities of clinical study submissions in Europe.



#### Connect with 700+ Swiss founders Join the Swisspreneur community


Tap into the hive mind of over 700 Swiss startup founders. Exchange on e.g. how to set up contracts for your globally distributed team, or how to best keep your seed round investors up-to-date, and much more...

[Join the community](#)

#### Export Award 2025

##### Internationally successful companies wanted

With the Export Award, Switzerland Global Enterprise honors internationally active companies with an impressive expansion strategy and innovative approach to market cultivation. The award will be presented to a Swiss or Liechtenstein company at a ceremony on the occasion of the International Trade Forum on April 30, 2025, at the Congress Center Basel. [Apply by January 15, 2025.](#)





#### The power of international collaboration

##### Discover Dutch-Swiss synergies in life sciences - December 10-12 Connecting the pharma R&D dots for a healthy future


The [Global Village](#) platform of the Swiss Biotech Association connects the Swiss biotech hub with other key biotech hubs. International delegations use it at the Swiss Biotech Day, and throughout the year joint working groups, site visits, and a network of biotech decision-makers are formed to strengthen the exchange between Switzerland and other countries and regions.

Discover new partnerships, explore cutting-edge innovations, and strengthen ties between the Swiss and Dutch life sciences ecosystems. Have a look at the [program](#). For more info or registration, please [directly contact Laura Duran or Niels van Leeuwen via email.](#)



### Swiss Biotech Report 2024

Reliable partners beyond borders





### Swiss Biotech Directory 2024

1 Nation 1 Biotech Cluster





### Annual Report 2023

The central resource for the Swiss biotech industry

With our monthly newsletter you stay ahead in the dynamic biotech landscape with the latest industry insights and opportunities

Our print publications are distributed at events and by direct mailings



# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

## Swiss Biotech Success Stories demonstrate the power and potential of the industry

**The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.**



Switzerland is one of the world's leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 50,000 jobs and, together with the pharmaceutical and chemical industries, accounts for almost half of Swiss exports.

To make the industry's impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational,

medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

"It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive," says Michael Altorfer, CEO of the Swiss Biotech Association. "Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech."

### 12 success categories

- ▶ Completed achievement with lasting impact
- ▶ Scientific breakthrough
- ▶ New technology
- ▶ Strong impact on society
- ▶ Product approval and sustainable revenues
- ▶ Important IP, innovative deal-making, acquisition
- ▶ Involvement of one or more Swiss citizens
- ▶ Swiss-based company / institution
- ▶ Creation of jobs in Switzerland
- ▶ Other aspect with a direct link to Switzerland
- ▶ Enabler for the biotech industry
- ▶ Swissness: Think global, made in Switzerland




## An independent jury of experts annually selects the Swiss Biotech Success Stories winners




**Jürg Zürcher**

President of the jury  
Independent biotechnology  
leader and expert



**Igor Fisch**

President Fongit  
CEO & Co-Founder New  
Biologix



**Stefanie Flückiger-  
Mangual**

CEO and Co-Founder  
Tolremo



**Gabrielle Gache**

Head of Business  
Development (EMEA)  
Santen Pharmaceutical



**Gabriela Güntherodt**

EY Partner & Biotech  
Sector Leader Switzerland/  
Europe West



**Chandra P. Leo**

Investment Advisor  
Private Equity HBM Partners



**Daniela Marino**

Chief Executive Officer and  
Co-Founder Cutiss



**Thomas Staffelbach**

Secretary of the jury  
TS Kommunikation

A big thank you to our sponsor:



The Swiss Biotech Success Stories Awards are also supported by:

**WISSENSCHAFT.  
BEWEGEN**  
GEBERT RUF STIFTUNG

| Basel-Stadt | TS Kommunikation

# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



- ▶ Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.



Werner  
Arber

- ▶ Werner Arber, Swiss microbiologist and geneticist, won the 1978 Nobel Prize in Physiology or Medicine for his discovery of restriction endonucleases. His groundbreaking research in the field of molecular genetics was instrumental in the development of biotechnology.

## BACHEM

- ▶ Bachem situated in Allschwil is a leading company specializing in development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products and services for research, clinical development and commercial application to pharmaceutical and biotechnology globally



- ▶ Basilea Pharmaceutica in Allschwil is a biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives. They are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.



- ▶ Biogen in Baar is a leading biotechnology company that pioneers innovative science and delivers new medicines to transform patient's lives. A broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy and the state-of-the-art biologics manufacturing facility in Luterbach are proof of Biogen's pioneering approach.



- ▶ Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Millions of patients benefit from their therapies every year.





- ▶ ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATech platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.



- ▶ The foundation promotes scientific research on neuromuscular diseases (myopathies) affecting children and adults. It awards grants to young researchers and has provided seed funding for two startups. It has established a scientific forum to encourage exchange of ideas, and also supports centers which care for patients.



- ▶ Genedata, global market leader for software solutions that digitalize data-rich and complex bio-pharmaceutical R&D processes, enables an R&D revolution driven by precision medicines and artificial intelligence approaches. It helps the industry to deliver innovative biotherapeutics, vaccines and cell & gene therapies faster.



- ▶ The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.



- ▶ Helsinn, an important employer in Ticino, has a broad portfolio of marketed cancer care products and a deep development pipeline. It has built significant R&D and manufacturing capacities, also advances patient care and supports healthcare innovation with its investment fund.



- ▶ Humabs BioMed, subsidiary of Vir Biotechnology, uses its immunologic expertise and cutting-edge technology to combat infectious diseases and other serious conditions. They are a pioneer in the discovery, engineering, and development of human monoclonal antibodies, e.g. crucial for fighting Ebola and COVID-19, and have helped transform the infectious disease landscape.

# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



Etienne  
Jornod

- ▶ Etienne Jornod, Swiss entrepreneur, was Executive Chairman of the Vifor-Galenica Group delivering 25 consecutive double-digit net profit growth, supporting millions of patients and creating thousands of jobs. In 2020, he acquired OM Pharma with friends, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise.

## Lonza

- ▶ Lonza is one of the world's largest healthcare manufacturing organizations, serving pharmaceutical, biotech and nutritional markets. Lonza's work enables its customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.



- ▶ Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.



- ▶ Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.



- ▶ The advanced technologies in protein expression by Selexis, based in Plan-les-Ouates, provide biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. In 2017, Selexis was acquired by JSR and integrated into KBI Biopharma in 2023.



- ▶ SOPHiA GENETICS generates clinically actionable insights and improved patient outcomes from a global data-sharing network. They democratize data-driven medicine globally through a cloud-based, decentralized SaaS platform, empowering shared insights among clinicians and researchers, and aiming for equal access to knowledge and improved clinical outcomes.



Hans-Peter Strebel

- ▶ Dr. Hans-Peter Strebel founded Fumapharm AG with three other scientists in 1983. Its successful research led to the development of Tecfidera, a disease modifying therapy for relapsing multiple sclerosis (MS). More than 600,000 patients worldwide have already benefited from the therapy.



- ▶ The trio of foundations has been supporting biotech startups with great success thereby making a significant contribution to the growth of the Swiss biotech industry. They share the nomination for the Swiss Biotech Success Stories Award.




- ▶ This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.



Use this QR code to find more information about the Swiss Biotech Success Stories

## In the media

National and international coverage of the Swiss biotech industry's achievements helps promote the value of our research contributions, products, and technologies.



# SWISS BIOTECH DAY 2026

© Swiss Biotech Association

May 4–5, 2026  
Congress Center Basel

## What you can expect:

- › Welcome reception on May 3
- › Meet over 2,500 senior experts from the life science industry
- › More than 100 exhibitors and the Global Village with international delegations from all over the world
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematic company pitching sessions and panel discussions
- › Swiss Biotech Success Stories Awards
- › Swiss Biotech Report 2026
- › Pre-scheduled one-to-one partnering meetings
- › General Assembly of the Swiss Biotech Association



Sign in on our website at  
[swissbiotechday.ch](https://swissbiotechday.ch)  
and stay updated about any news.

Host & event manager:

Logistics & marketing partner:



## Partner network provides crucial advantages

**The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.**

### **Access to a wider pool of resources**

By partnering with other organizations, we can access a broader range of resources and exchange with specialized industry stakeholders. Our partnerships strengthen our voice and leverage our impact.

### **Increased credibility and visibility**

Collaboration with reputable partners and policy makers increase the credibility and visibility of our association. This builds trust and confidence, and helps to optimize the framework for a successful industry development.

### **Improved information exchange**

Our partners enable us to access and transfer more knowhow, to provide our stakeholders with privileged information, networking opportunities, international connectivity and access to technologies.

### **Amplified support for Swiss biotech ecosystem**

Our partners help promote and improve our platforms and thus accelerate and amplify the support we can provide to the Swiss biotech stakeholders.



Check out  
our partners

**The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.**



## Income statement

In CHF	2024		2023	
	Expenses	Income	Expenses	Income
Membership fees		1,073,000		928,000
International projects		0		2,929
National projects		1,655,238		1,085,780
Website & community platform		1,600		1,400
Swiss Biotech Success Stories		5,000		13,000
Swiss Biotech Report		58,000		58,000
Swiss Biotech Directory		19,110		23,870
Increase/decrease bad debt provision		-5,000		-2,000
<b>Total income</b>		<b>2,806,948</b>		<b>2,110,979</b>
Fees to other associations	51,977		25,476	
International projects	69,235		60,882	
National projects	1,594,422		1,153,021	
Swiss Biotech Success Stories	10,097		15,615	
Decrease tied capital "Swiss Biotech Success Stories"	-3,000		-2,000	
Swiss Biotech Report	76,174		73,079	
Swiss Biotech Directory	29,889		32,150	
Website & community platform	130,440		82,735	
<b>Association activities expense</b>	<b>1,959,234</b>		<b>1,440,958</b>	
Management fees <sup>1</sup>	376,143		329,548	
Accounting & member support	240,018		167,399	
Office rent & administration	28,635		32,436	
Consulting	23,279		7,398	
Public relations	122,748		112,652	
<b>Other operating expenses</b>	<b>790,823</b>		<b>649,434</b>	
<b>Financial income result</b>	<b>12,624</b>		<b>8,943</b>	
<b>Expenses from previous reporting period</b>	<b>132</b>		<b>0</b>	
<b>Tax expenses</b>	<b>311</b>		<b>234</b>	
<b>Net profit for the year</b>		<b>43,824</b>		<b>11,410</b>

<sup>1</sup> Management fees related to events and promotional products are directly booked to the respective project



# Balance sheet

	Balance Sheet 31.12.2024		Balance Sheet 31.12.2023	
In CHF	Assets	Liabilities	Assets	Liabilities
<b>Assets</b>				
Cash and cash equivalents	395,347		263,206	
Accounts receivable	71,937		20,385	
Accrued income & prepaid expenses	14,095		80,370	
<b>Total assets</b>	<b>481,379</b>		<b>363,961</b>	
<b>Liabilities and equity</b>				
Accounts payable		170,910		113,523
Accrued expenses & deferred income		76,247		57,040
Association equity		131,239		131,239
Tied capital for SBA Success Stories		0		3,000
Tied capital for SBA Sounding Board		10,000		10,000
Retained earnings		49,160		37,750
Net result of the year		43,824		11,410
<b>Total liabilities and equity</b>		<b>481,379</b>		<b>363,961</b>

# Auditor's report



Phone +41 44 444 35 55  
www.bdo.ch  
zurich@bdo.ch

BDO Ltd  
Schiffbaustrasse 2  
8031 Zurich

Report of the statutory auditor on the limited statutory examination  
to the general meeting of

Swiss Biotech Association (SBA), Zürich

As statutory auditor, we have examined the financial statements (balance sheet, operating statement and notes) of Swiss Biotech Association (SBA) for the financial year ended 31 December 2024.

These financial statements are the responsibility of the association board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of entity personnel and analytical procedures as well as detailed tests of entity documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the articles of association.

Zurich, 31 January 2025

BDO Ltd

A blue ink signature of Manuel Lüthi on a light blue grid background. A small red circular stamp is visible in the top right corner of the signature area.

Manuel Lüthi  
Leitender Revisor  
Zugelassener Revisionsexperte

A blue ink signature of Stefan Brack on a light blue grid background. A small red circular stamp is visible in the top right corner of the signature area.


Stefan Brack  
Zugelassener Revisionsexperte

Enclosure  
Financial statements

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.

## Clear focus on what really matters


Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.



The rapid expansion of our member base provides strong motivation to the Swiss Biotech Association board and management team. As we foster the formation of an effective Swiss biotech community, more and more members recognize the value of peer-to-peer exchange and the benefit of jointly building a pool of biotech talent, biotech investors, and an international network of collaborations and alliances.

We encourage continuing our active dialogue to jointly shape the future of the Swiss biotech hub and its framework, thereby keeping it on its successful track.

We enhance the visibility of biotech companies





These members benefit from a cost-effective marketing opportunity, with their logos featured for a year on our communication tools.


## Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (s. page 37).

### Swiss Life's pension fund

With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.


**SWISS BIOTECH**'s Life



### Helvetia's business insurance


Our members can cover their business risks with Helvetia's individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.

**helvetia**  
Your Swiss Insurer



### LubioScience's portfolio

Our members benefit from special discounts on LubioScience's entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.



**LUBIO SCIENCE**  
THE REAGENT PLATFORM

---

## ProcEurope's laboratory supplies

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific by the European Life Sciences Purchasing Consortium.



---

## BioCentury's market research


A complimentary test access to BioCentury's Intelligence platform, as well as discount on the subscription helps our members' executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.



---

## Springer Nature's leading publications

The world's leading scientific and technical publisher Springer Nature offers our members' subscription discounts between 25% and 50% for some of their most exciting products.



# SPRINGER NATURE

## Swiss Biotech Association board and management

As our member base has grown to almost 600 members, the management team has also gradually expanded. The Swiss Biotech Association now has liaisons in Basel/Northwestern Switzerland, Romandie, Bern/Midlands, Zürich/Eastern Switzerland, and Svizzera Italiana.

### The board

---



**Patrick Amstutz, PhD**  
President  
CEO Molecular Partners



**Jurgi Camblong, PhD**  
Vice President  
CEO SOPHiA GENETICS



**Igor Fisch, PhD**  
Vice President  
President Fongit,  
CEO & Co-Founder  
New Biologix



**Anne Marie de Jonge-Schuermans, PhD**  
Vice President  
Global Head Biologics &  
Injectables Operations  
Sandoz



**Bettina Ernst, PhD**  
Vice President  
CEO BERNINA Bioinvest



**Filippo Riva**  
Vice President  
Managing Director  
Humabs Biomed





**It supports association chapters for diagnostics, healthtech, and industrial biotech companies, and manages online platforms and events to support selected stakeholder groups or cross-industry key topics (s. pages 13–15).**

**The management team**

---



**Michael Altorfer, PhD**  
CEO



**Sabine Bamert**  
Head of communication



**Patrick Imwinkelried**  
Accounting  
Wespi & Partner



**Annamaria Kauzlaric**  
Member support  
Diagnostics & healthtech  
chapters



**Natasha Konstantinova**  
Head talent pool & Swiss  
Biotech Association  
Academy



**Maximilien Murone, PhD**  
Liaison Basel |  
Northwestern Switzerland



**Fabio Napoletano**  
Head Business Development  
Liaison Bern



**Rachel Ougier Simonin**  
Business processes &  
IT infrastructure



**Tiziana Rosa, PhD**  
International relations &  
Liaison Svizzera Italiana



**Franz Waibel, PhD**  
Head Global Village



**Aditya Yellepeddi**  
Liaison Romandie  
Industrial biotech chapter

# Supporting the Swiss biotech hub: Objectives 2025

**The 2025 objectives of the Swiss Biotech Association align with one of the four mission pillars (s. page 12) or aim to enhance the financial flexibility and operational effectiveness of the association itself.**



## Favorable frameworks

Favorable framework conditions for Swiss biotech companies facilitate access to global talent, funding, and innovative technologies, while ensuring robust protection of intellectual property, an effective path to regulatory approval, and reliable market exclusivity terms.

To strengthen its impact, the Swiss Biotech Association has established a strong network of partners in Switzerland and abroad, all aligned with a common objective: To optimize global framework conditions for biotech startups and SMEs (see partner network on page 26).

In 2025, we will focus on:

- Re-establishing Switzerland's full association with the Horizon Europe R&D program
- Opposing proposals that aim to weaken the international IP framework and risk undermining biomedical innovation
- Helping to shape policies for the life sciences industry that foster innovation, attract funding, harmonize and accelerate regulatory approvals, and provide reliable market exclusivity periods
- Using our leading position in life sciences R&D to foster international collaboration and help innovate the global healthcare system through international alliances



## Securing essential resources

In support of the second mission pillar, we develop platforms and tools that enable Swiss-based biotech companies to access international talent, funding, and emerging technologies.

Our industry is growing at a rate of approx. 5% annually. This means that each year, we need to attract an additional 2,000–3,000 biotech professionals, while also replacing those who retire.

Swiss biotech SMEs invest approximately 2.5 billion CHF in R&D projects each year. While they generate some income through sales and milestone payments, they need to attract around 1.5–2 billion CHF in new funds from global investors to support the current size and growth rate of the industry.

In 2025, we aim to support this by:

- Promoting the Swiss Biotech Orbit platform (p. 9) matching talents and jobs
- Attracting educational opportunities to our Academy platform
- Promoting our Swiss Biotech Ventures platform (p. 8) to facilitate financing and partnering
- Organizing a pre-event for biotech investors only at the Swiss Biotech Day
- Expanding the number of preferential business solutions that help our members reduce operating costs



## Networking and information exchange

Our flagship event, the Swiss Biotech Day, will again play a central role in fostering information exchange and providing national and international networking opportunities. Since 2021, it has expanded by 40% every year and attracted around 2,500 participants from more than 40 countries in 2024.

Now we will focus on qualitative growth by offering specific side events for global biotech investors and pharma partners. With mentoring booths and Swiss cluster booths, we also aim to provide valuable insights and information exchange, as well as increased interaction between Swiss biotech stakeholders and international partners.

In 2025, we plan to strengthen networking opportunities by:

- Driving qualitative growth of the Swiss Biotech Day, solidifying its position as a premier global partnering event for biotech executives
- Enabling the formation of bilateral biotech communities between Switzerland and strong international biotech hubs
- Expanding the Swiss R&D Biotech, CFO, and HR meeting platforms to support peer-to-peer know-how exchange and provide important feedback loops for the association
- Engaging with various biotech investor groups and supporting the Deep Tech Nation Switzerland Foundation in developing investment opportunities for institutional investors



## Promotion and awareness

For 14 consecutive years, Switzerland has led the global innovation index published by the World Intellectual Property Organization, and the Swiss biotech hub is an important factor in this assessment.

Promoting the contribution and value of the more than 1,500 Swiss-based biotech companies remains the key objective of our fourth mission pillar. While we promote the value of our products and technologies, we also need to build awareness of the needs of Swiss biotech startups and SMEs to ensure that they can continue to be an essential driver of Swiss innovation power.

To support this, in 2025 we will:

- Publish the digital and print editions of the Swiss Biotech Directory
- Publish the Swiss Biotech Report 2025, highlighting the power of international alliances
- Promote the Access Consortium of Switzerland, Australia, Canada, the UK, and Singapore
- Present the Swiss Biotech Success Story Awards to the 2025 laureates
- Establish the Swiss life sciences communication alliance

# List of 593 members, December 31, 2024

112 new members joined the association in 2024, shown in red

3B Biotech Research Sagl  
3T Biosciences Europe GmbH  
**4Bases SA**  
4G Clinical B.V.  
7AlpsBio GmbH  
AB2 Bio Ltd  
**Abbmira Therapeutics AG**  
abc biopply AG  
abcDNA GmbH  
ABCDx SA  
Abologix Sàrl  
AC Bioscience SA  
AC Immune SA  
ACM Biosciences AG  
ACROBiosystems AG  
Activen SA  
ADC Therapeutics SA  
Addex Therapeutics Ltd  
Adienne Pharma & Biotech SA  
Adiposs SA  
Adolf Kühner AG  
Adoram Therapeutics SA  
Advanced Clinical Switzerland GmbH  
**Advesya AG**  
Advitech Consulting SA  
aiNET GmbH  
Akceso Advisors AG  
Alentis Therapeutics AG  
**Alira Health**  
Alitheia Genomics SA  
**Allegría Therapeutics AG**  
**AllesHealth GmbH**  
Alloy Therapeutics (Switzerland) AG  
**Alpha Lyncis SA**  
**AlphaMol Science AG**  
AlphaOnco Swiss SA  
Alphastrat GmbH  
**Altamira Therapeutics AG**  
Altasciences  
Altorfer Engineering GmbH  
AlveoliX AG  
Amal Therapeutics  
Amazentis SA  
**Amphasys AG**  
AmphiliX AG  
**Amporin Pharmaceuticals AG**  
AMYRA Biotech AG  
AnaPath Services GmbH  
Anaveon AG  
Anjarium Biosciences AG

**Ansea AG**  
anteris Helvetia AG  
Antion Biosciences SA  
Aphaia Pharma AG  
Apricot Therapeutics AG  
Aptissen SA  
Araris Biotech AG  
Ariceum International AG  
**Arphamid Therapeutics GmbH**  
**ArtBio GmbH**  
ARTIDIS AG  
ASC Oncology Schweiz AG  
Asceneuron SA  
Asterivir SA  
Astra Therapeutics AG  
**Atanis Biotech AG**  
Athebio AG  
ATLyphé AG  
Atopia Therapeutics SA  
Aukera Therapeutics GmbH  
Aurealis Therapeutics AG  
Auregen Biotherapeutics SA  
Avance Basel GmbH  
**Avenza Consulting Sarl**  
Avrion Therapeutics AG  
**axcura AG**  
Axon Lab AG  
Azafaros Switzerland AG  
**B SQUARED Sarl**  
Baccinex SA  
Bachem AG  
BakerHicks AG  
Baliopharm AG  
**Basel Biotech Consulting GmbH**  
Basilea Pharmaceutica Ltd.  
Bavarian Nordic Berna GmbH  
BC Platforms AG  
Becton Dickinson AG  
BERNINA BioInvest AG  
BIDECO AG  
BigOmics Analytics SA  
Bio-Rad Laboratories AG  
**Bio-Techné AG**  
Bio-Technopark Schlieren-Zürich  
BioArk SA  
BioConcept AG  
BioCopy AG  
Bioengineering AG  
Biogen International GmbH  
BioLingus

BioMedPartners AG  
BiomedVC AG  
Bionter AG  
Biopôle SA  
**Bioscibex SA**  
Biosynth AG  
BioVersys AG  
**BioXpress Therapeutics SA**  
blsc - bihlmann life science communication  
Blueprint Medicines (Switzerland) GmbH  
Boehler Life Science Advice  
Bonetti & Partner GmbH  
Bright Peak Therapeutics AG  
Bromatech (Suisse) SA  
Bucher Biotec AG  
Büchi AG  
Bühlmann Laboratories AG  
Caland SA  
**CalicoBiosystems SA**  
Calliditas Therapeutics Suisse SA  
Cancer Research and Biotechnology AG  
Canlion AG  
CanVirex AG  
Caparna AG  
Carbogen Amcis AG  
Catalent Pharma Solutions GmbH  
Catalyze Switzerland GmbH  
CDR-Life AG  
CEBIS International  
Ceidos SA  
Celerion Switzerland AG  
**Cellerys AG**  
Cellestia Biotech AG  
CELLnTEC advanced cell systems AG  
**Cellula Therapeutics SA**  
cellvie AG  
Celonic AG  
Centenara Labs AG  
Cerbios-Pharma SA  
Cerdia International GmbH  
certus molecular diagnostics ag  
Cetacea Consulting GmbH  
**chAlron SA**  
**Chelonía SA**  
Chemengineering Switzerland AG  
Chinsiders GmbH  
Choose Life BioTech SA  
**ChromaCon AG**  
Cilatus Biopharma Consulting AG  
CimArk SA



Cimeio Therapeutics AG	Eurofins BioPharma Product Testing Switzerland AG	Helsinn Healthcare SA
CIS BioPharma AG	Eurofins Genomics	Helvetica Biotech Sarl
Citeline	Eviden AG	Helvetica Health Care Sarl
Clear Solutions Laboratories AG	Evitria AG	HEMEX AG
ClearView Healthcare Partners Switzerland GmbH	<b>EvlaBio AG</b>	HemostOD SA
<b>Clinigen Healthcare Switzerland SARL</b>	ExcellGene SA	HGF GmbH
Clinipace AG	ExpertInova AG	Hoffmann & Partner AG
ClinOps Advisory Turner GmbH	Expleo Technology Switzerland AG	Homburger AG
<b>Complyomics Sarl</b>	F. Hoffmann- La Roche AG	Horgen Labs GmbH
Connectors Verbindungstechnik AG	FABLE GmbH	House of Lab Science AG
Coulter Partners	<b>FatiAbGen International GmbH</b>	Humabs BioMed AG
<b>Cradle Switzerland AG</b>	FB Global Regulatory Consulting and Coaching	Hyperbolic Holdings GmbH
CRB Group GmbH	<b>Fidia Pharma (Switzerland) SA</b>	<b>IBR Inc. Institute for Biopharmaceutical Research</b>
CROSS Research SA	FimmCyte AG	<b>ICARE Laboratoire Switzerland Sarl</b>
CSEM	FinalSpark SARL	<b>ICE Biopharma GmbH</b>
CSL Behring AG	Fischer PreclinTox Consulting	Ichnos Sciences SA
CTC Resourcing Solutions AG	Floratek Pharma SA	ICON Clinical Research (Switzerland) GmbH
Culture Collection of Switzerland AG	FluoSphera SA	iCure SA
Curare Swiss AG	Fondation EspeRare	Ideogen AG
Curatis AG	Fortrea Switzerland AG	Idorsia Pharmaceuticals Ltd.
Cureline AG	Forty51 Advisors AG	IE Life Science Engineering AG
<b>Curie.Bio</b>	FoRx Therapeutics AG	ImmunOs Therapeutics AG
CUTISS AG	Fritz Gyger AG	<b>ImmunSkills SA</b>
<b>CxO SA</b>	Future Health Pharma GmbH	<b>In Virtuo Laboratories Sagl</b>
<b>Cybiome GmbH</b>	Galapagos GmbH	Incaptek Sarl
Cytiva Europe GmbH	Galser SA	InCephalo AG
Cytosurge AG	<b>Ganda Business Solutions AG</b>	Incyte Biosciences International Sarl
Cyxone Switzerland AG	GBiotech Sarl	Infinity Communications Sarl
D36.ch Sarl	Genedata AG	Infors HT Schweiz
Dao Tun GmbH	Genesupport SA	InkVivo Technologies AG
Debiopharm International SA	GeNeuro SA	InnoMedica Holding AG
Delta Medical Promotions AG	<b>Genevant Sciences GmbH</b>	INOFEA AG
Dimericon Therapeutics AG	GenSearch Switzerland GmbH	<b>inSEIT AG</b>
Dinaqor AG	<b>GenXBioscience AG</b>	InsideReg Sarl
DPS Engineering Switzerland GmbH	<b>GIO Therapeutics AG</b>	InSphero AG
DrM, Dr. Mueller AG	GliaPharm SA	<b>Institut de formulation des vaccins (CH) SA</b>
EAI Europe AG	GlycoEra AG	Integra Biosciences AG
<b>Ectica Technologies AG</b>	GMT Fine Chemicals SA	Integrated Biologix GmbH
<b>Edelweiss Connect GmbH</b>	Gnubiotics Sciences Sarl	Integrated Project Services GmbH
EffRx Pharmaceuticals SA	Granite Bio AG	IntelDrug Consulting Pospišil
<b>Eli Lilly (Suisse) SA</b>	GT Gain Therapeutics SA	InterAx Biotech AG
<b>Elionova AG</b>	<b>GTP Bioways CDMO</b>	Inthera Bioscience AG
Elthera AG	GXP CONSULTING Switzerland GmbH	IONctura SA
<b>Emtex AG</b>	Haya Therapeutics SA	IPS Biopharma AG
<b>Enable Biotech AG</b>	HBM Partners AG	IQone Healthcare Switzerland SA
Endogena Therapeutics AG	headcount AG	IQVIA AG
<b>Enzene Inc.</b>	Healiva SA	<b>Ironwood Pharmaceutical</b>
<b>EPIC Suisse AG</b>	Health Advances GmbH	Isospec Analytics SA
EraCal Therapeutics Ltd	Healthecon AG	J. Lamarck Asset Management SA
<b>Ernst &amp; Young AG</b>	HekeTiss SA	Jacobs Switzerland GmbH



# List of 593 members, December 31, 2024

112 new members joined the association in 2024, shown in red

Jagotec AG - Vectura Fertin Pharma  
JFG Life Sciences Stiftung der Universität Basel  
JMP Software, SAS Institute GmbH  
**Justin Stindt Consulting AG**  
**Juvion Life Sciences Sarl**  
**KBI Biopharma SA**  
**Kellerhals Carrard**  
Kisco Sarl  
KPMG AG  
KVALITO AG  
Labatec Pharma SA  
Labcorp Central Laboratory Services Sarl  
LabForce AG  
Laevoroc Oncology AG  
LaForce Business Solutions Sagl  
LAGOSTA SA  
LaRive Bio AG  
LATAM Pharma Innovative Ventures AG  
Laves-Arzneimittel GmbH  
leadXpro AG  
Legacy Healthcare (Switzerland) SA  
Leman Biotech Lausanne SA  
**Lenz & Staehelin**  
Life Sciences Executive Search SARL  
Light Chain Bioscience - NovImmune SA  
LimmaTech Biologics  
Limula SA  
Linkster Therapeutics AG  
Lonza AG  
LS Instruments AG  
LubioScience GmbH  
Lucerna Chem AG  
**Luminance Health GmbH**  
Lunaphore Technologies SA  
LYO-X AG  
**MabTree Biologics AG**  
**Mabylon AG**  
Maxia Strategies GmbH  
MaxWell Biosystems AG  
**McArthur and Associates GmbH**  
MD Bioproducts GmbH  
Med Discovery SA  
**Mederis**  
MEDEXpansion Sarl  
**Medistri SA**  
**Medlabdia AG**  
MedScienceSwiss AG  
**Medvisis Switzerland AG**  
MedXCell SA  
Memo Therapeutics AG

Menarini Biotech srl  
Merz/Anteis SA  
MesenFlow Technologies Sarl  
**metaLead Therapeutics AG**  
metaShape Pharma AG  
MetrioPharm AG  
**MF Life Sciences GxP Consulting GmbH**  
Micro-Sphere S.A.  
Microsynth AG  
**MicThera Sagl**  
Miltenyi Biotec Swiss AG  
**Mirum Pharmaceuticals AG**  
MOD1 AG  
Molecular Partners AG  
Monte Rosa Therapeutics AG  
Moonlight AI Sarl  
Mosanna Therapeutics AG  
MPC Therapeutics SA  
MRGN Advisors Sarl  
MUVON Therapeutics AG  
MV BioTherapeutics SA  
Nagi Bioscience SA  
Nathalie Jenni Consulting GmbH  
Navignostics AG  
NBE-Therapeutics AG  
NCMA Consulting GmbH  
NDA Regulatory Service Switzerland GmbH  
NegotiumBio Schweiz GmbH  
Nemis Technologies AG  
Neovii Pharmaceuticals AG  
Neurimmune AG  
**Neurosterix Pharma Sarl**  
Newbiologix SA  
Nexco Analytics Sarl  
NexMR GmbH  
**Nikon Europe B.V.**  
Nodes Advisors AG  
Noema Pharma AG  
Nouscom AG  
NovaGo Therapeutics AG  
Novaremed AG  
Novartis Pharma AG  
**Novassay SA**  
Novigenix SA  
Novochizol SA  
**Nuclidium AG**  
Numab Therapeutics AG  
NXI Therapeutics AG  
**ObelysQ SA**  
OCCIDENT Group AG

Oculus Operations Sarl  
Oculox Technologies SA  
Olgram SA  
OM Pharma Ltd  
OMNI Life Science GmbH  
**OmnilinX Therapeutics**  
Oncodesign Services  
Onena Medicines AG  
ONtrack Biomedical AG  
Onward Therapeutics SA  
oprandi & partner romandie sa  
**Oractive Swiss AG**  
Oriento SA  
Orio Therapeutics SA  
Orion Biotechnology Switzerland  
**Orphan Drug Consulting**  
Oryl Photonics SA  
Ottien Life Sciences Consulting Sarl  
P&G MedChem AG  
**Paola Valinotti Aostri - Access2Health Consulting**  
PAREXEL International (CH) AG  
**Parithera SA**  
PDC Therapeutics SA  
Peleven AG  
PeptART Bioscience GmbH  
Peptone Switzerland AG  
Perseo Pharma AG  
Phargentis SA  
Pharma-Consulting ENABLE GmbH  
PharmaBiome AG  
**PharmaKorell GmbH**  
PharmNDev Experts SA  
Pharvaris GmbH  
Pheida AG  
**Phialogics AG**  
**Philip Morris Switzerland Sarl**  
Philochem AG  
Pilatus Biosciences SA  
Planetary SA  
**PLUS Life Sciences Consulting Sarl**  
plusbiome AG  
PLX Healthcare Services (Switzerland) AG  
PMS Process Management System Sarl  
Polaroid Therapeutics AG  
PolyPeptide Group AG  
**Populus Bio Sarl**  
Porton Pharmaceutical Chemicals GmbH  
Praed Pharmaceuticals Ltd  
**Prasfarma**  
**Preclina Europe GmbH**



PreComb Therapeutics AG	Selmod GmbH	Tigen Pharma SA
Promega AG	Senn Resources AG	Tigermед Swiss AG
Prometheus Life Technologies AG	Sferalp SA	TissueLabs Sagl
ProteoMediX AG	SFL Pharma GmbH	tiventa AG
Provectis Helathcare AG	SGS Analytics Switzerland AG	TOLREMO therapeutics AG
PSI CRO AG	SGS Life Sciences Geneva	Toolpoint for Lab Science
Pureos Bioventures	Shimadzu Schweiz GmbH	Topadur Pharma AG
PVP Therapeutics AG	SICPA SA	Trialize AG
Qanatpharma AG	Skyvor Medical AG	Tridek-One Therapeutics SAS
QBDC GmbH	Socorex Isba SA	Trillione GmbH
Qiáo Advisors GmbH	SOLID Drug Development SA	UCB Pharma AG/UCB Farchim SA
Quant Biomarkers AG	Solvias AG	USP Switzerland AG
Quartz Bio SA	Somagenetix AG	Vaccentis AG
Quercis Pharma AG	Sophia Genetics SA	Vaderis Therapeutics AG
RADAR RP Sàrl	Sotio Biotech AG	valuationLAB AG
Rambam AG	SP Groups SA	Vandria SA
RDP Pharma AG	SpacePharma SA	Venture Valuation
Recolony AG	Spexis AG	Versameb AG
Reconnect Labs AG	Springer Nature Ltd	VILS Switzerland GmbH
Recordati AG	STALICLA SA	Viopas Venture Consulting GmbH
Redbiotec AG	Stämm Vegh SA	Vir Biotechnology International GmbH
Regen Lab SA	Stobbe Pharma GmbH	VirdisGroup Sàrl
REM Analytics SA	Strategy Consulting Dr. Rudolf K. Sprüngli	Virometix AG
Remap Consulting GmbH	Streefkerk Life Sciences Consultancy (SLSC)	VISCHER AG
Renaldee AG	Stromal Therapeutics AG	Voisin Consulting Life Sciences
Repertoire Immune Medicines AG	Sumitomo Pharma Switzerland GmbH	Volv Global SA
Resea Biotec GmbH	Superlab Suisse AG	VTU Engineering Schweiz AG
Resistell AG	Supply Chain Operations SA	Walder Wyss AG
RespAct GmbH	swati AG	Watson-Marlow AG
Rhizen Pharmaceuticals AG	Swiss Biotech Center SA	Wemedoo AG
Risklick AG	Swiss Consultant-Network GmbH	Wipro Ltd. Geneva branch
Roumai Medical (Switzerland) SA	Swiss Rockets AG	Witt/Kieffer Schweiz AG
Rowestil Consulting GmbH	Switzerland Global Enterprise	WuXi AppTec
Sai Life Sciences Ltd	Swizzard Pharma AG	Wyss Zurich
Saiba AG	SynDermix AG	Xcenda Switzerland GmbH
SAKK	Synendos Therapeutics AG	XCubeBio AG
Salmon Pharma GmbH	Syneos Health Switzerland GmbH	Xenometrix AG
Salvina Therapeutics AG	Syrhatech SA	Xlife Sciences AG
Santerus AG	T-Oncology AG	Ymmunbio AG
Santhera Pharmaceuticals (Switzerland) AG	T3 Pharmaceuticals AG	Yokogawa Innovation Switzerland GmbH
Sartorius Stedim Switzerland AG	Talisto GmbH	YONI Solutions SA
Scaillyte AG	Tandem Therapeutics AG	Zambon Biotech SA
SCG Siam Cement Group	TargImmune Therapeutics AG	Zeta CH AG
Schedio SA	ten23 health AG	
Schmidt Versicherungs Treuhand AG	Tenpoint Therapeutics GmbH	
Seagen International GmbH	The Jackson Laboratory	
Securecell AG	The RSA Group	
SEED Biosciences SA	therainnova AG	
Sefunda AG	Thermo Fisher Scientific Biologics Lengnau	
Seito Biologics AG	Thermo Fisher Scientific Life Technologies	



Swiss Biotech Association  
Löwenstrasse 11  
8001 Zürich  
Switzerland

T: +41 44 455 56 78

[info@swissbiotech.org](mailto:info@swissbiotech.org)  
[swissbiotech.org](http://swissbiotech.org)